Will be administered trial dose of Covaxin tomorrow, says Haryana minister Anil Vij

Haryana's health minister, Anil Vij, on Thursday, said that he will be administered a trial dose of 'Covaxin' on November 20.

Will be administered trial dose of Covaxin tomorrow, says Haryana minister Anil Vij
Haryana's health minister, Anil Vij (File Photo). Image Credit: ANI
  • Country:
  • India

Haryana's health minister, Anil Vij, on Thursday, said that he will be administered a trial dose of 'Covaxin' on November 20. Bharat Biotech's Covid-19 vaccine 'Covaxin' is beginning its Phase 3 clinical trials in Haryana from tomorrow.

"I will be administered a trial dose of Coronavirus vaccine i.e. Covaxin, a Bharat Biotech product, tomorrow at 11 am at Civil Hospital, Ambala Cantt under the expert supervision of a team of doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose," the health minister tweeted. On November 18, Vij had offered to become the "first volunteer" for Phase-III clinical trial of the vaccine

"Trial for the third phase of Covaxin a coronavirus vaccine product of Bharat Biotech to start in Haryana on 20th November. I have offered myself as the first volunteer to get vaccinated," Vij tweeted. In October, the Drugs Controller General of India gave permission to Bharat Biotech for conducting the Phase-III clinical trial for Covaxin

The Phase 3 trials will involve 26,000 volunteers across India and will be conducted in partnership with ICMR. It is the largest clinical trial conducted for a Covid-19 vaccine in India. Trial volunteers will receive two intramuscular injections about 28 days apart. Participants will be randomly assigned to receive Covaxin or placebo.

The trial is double-blinded, such that the investigators, the participants, and the company will not be aware of who is assigned to which group.Covaxin has been evaluated in about 1,000 subjects in Phase I and Phase 2 clinical trials, with promising safety and immunogenicity data. Volunteers who wish to participate in this trial should be adults over 18 years of age. (ANI)

Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.